VARIABLES DEL NEGOCIADOR RELACIONADAS CON UNA MAYOR EFICACIA EN EL PROCESO DE NEGOCIACIÓN

El presente trabajo versa sobre las variables asociadas a una mayor eficacia en el proceso de negociación. En primer lugar se ha realizado una instrucción teórica sobre conflicto, negociación y las variables asociadas a la eficacia negociadora. Además, se ha llevado a cabo un estudio de campo, descriptivo y transversal cuyos objetivos han sido analizar los factores que se relacionan con mayor eficacia en la negociación. A través de este, se solicitó participar a una muestra de 50 personas. La principal variable del estudio fue eficacia en la negociación, junto a esta se recogieron otras variables como variables sociodemográficas, inteligencia emocional, variables de personalidad, motivación y estilos de negociación. Los resultados han mostrado tanto en el análisis correlacional como en la regresión que las variables relacionadas con una mayor negociación son: claridad, evitación, dominación, tendencia al compromiso, mientras que extraversión se correlaciona inversamente. Finalmente, se ha realizado una comparativa por género, obteniendo diferencias significativas en atención, clima constructivo y neuroticismo.<br /

Self-rated health impact of COVID 19 confinement on inmates in Southeastern of Europe: a qualitative study

Abstract Introduction The COVID-19 pandemic necessitated the implementation of various measures within closed institutions like prisons to control the spread of the virus. Analyzing the impact of these measures on the health of inmates is crucial from a public health perspective. This study aimed to explore inmates’ subjective perception of the COVID-19 lockdown, the implemented measures, their physical self-perception, and their views on the vaccination process. Method Between April 2021 and January 2022, 27 semi-structured individual interviews and 1 focus group were conducted with inmates in a prison located in northwest Spain. The interviews were conducted in person and audio-recorded. Thematic content analysis was employed, utilizing methodological triangulation to enhance the coherence and rigor of the results. Results The analysis revealed two main themes and nine subthemes. The first theme focused on inmates’ perception of the implementation of protective measures against COVID-19 within the prison and its impact on their well-being. The second theme explored the pandemic’s emotional impact on inmates. All participants reported negative consequences on their health resulting from the measures implemented by the institution to contain the pandemic. However, they acknowledged that measures like lockdowns and mass vaccination helped mitigate the spread of the virus within the prison, contrary to initial expectations. Conclusion COVID-19 and related measures have directly affected the health of inmates. To improve their health and minimize the impact of pandemic-induced changes, community participation and empowerment of individuals are essential tools, particularly within closed institutions such as prisons

Células madre y sus exosomas como terapia avanzada para tratar la hernia incisional: prueba de concepto en modelo murino

An incisional hernia constitutes a tissue protrusion through a traumatic or surgical scar in the abdominal wall. Frequently, the treatment of the incisional hernia, as well as other types of hernia, involves the implantation of a surgical mesh to reinforce the weakened tissue. However, an exacerbated inflammatory response is commonly developed after this implantation, having serious consequences for the patient. Considering the immunomodulatory potential of mesenchymal stem cells (MSCs) and their exosomes (exo-MSCs), in this study we proposed that the administration of these two therapeutic products, together with fibrin sealants that are frequently used to fix surgical meshes, could have a beneficial biological and therapeutic effect that could help to modulate the inflammatory response and improve the success of the surgical mesh implantation. The results obtained in this work showed, in a murine model of incisional hernia, that exo-MSCs reduce M1 inflammatory macrophages infiltration and that there is a predominance of Th2-related cytokines in the surrounding tissue of MSCs or exo-MSCs treated meshes, favoring the macrophage polarization towards a M2 anti-inflammatory phenotype. This study concludes that mesh fixation with fibrin sealants co-administered with MSCs or exo-MSCs would have a beneficiary effect on the treatment of incisional hernia in terms of reduction of the inflammatory response and modulation of the foreign body reaction.Una hernia incisional consiste en una protrusión de tejido a través de una cicatriz traumática o quirúrgica en la pared abdominal. El tratamiento de este y de otros tipos de hernias pasa frecuentemente por la implantación de una malla quirúrgica para reforzar el tejido debilitado. Sin embargo, a menudo se produce una respuesta inflamatoria exacerbada que desemboca en diferentes complicaciones, teniendo consecuencias graves para el paciente.Considerando el potencial inmunomodulador de las células madre mesenquimales (MSCs) y de sus exosomas (exo-MSCs), en este estudio planteamos que la administración de ambos productos terapéuticos, conjuntamente con los selladores de fibrina que se utilizan frecuentemente para la fijación de las mallas quirúrgicas, podría ejercer un efecto biológico y terapéutico que ayudara a controlar esa respuesta inflamatoria y mejorara, por tanto, el éxito del tratamiento con mallas quirúrgicas.Los resultados obtenidos en este estudio mostraron, en un modelo murino de hernia incisional, que los exo-MSCs reducen la infiltración de macrófagos inflamatorios M1 y que existe una predominancia de citoquinas relacionadas con la respuesta Th2, y con ello, con la polarización de macrófagos hacia un fenotipo M2 antiinflamatorio, en el tejido circundante a las mallas en las que se vehicularon MSCs o sus exosomas.Este estudio concluye que la fijación de mallas quirúrgicas con selladores de fibrina combinados con MSCs o exo-MSCs tendría un efecto beneficioso en el tratamiento de la hernia incisional, en términos de reducción de la respuesta inflamatoria y modulación de una reacción exacerbada frente a un cuerpo extraño

Disposable electrochemical immunoplatform to shed light on the role of the multifunctional glycoprotein TIM-1 in cancer cells invasion

Detecting overexpression of cancer biomarkers is an excellent tool for diagnostic/prognostic and follow-up of patients with cancer or their response to treatment. This work illustrates the relevance of interrogating the levels of T-cell immunoglobulin and mucin domain 1 (TIM-1) protein as a diagnostic/prognostic biomarker of high-prevalence breast and lung cancers by using an amperometric disposable magnetic microparticles-assisted immunoplatform. The developed method integrates the inherent advantages of carboxylic acid-functionalized magnetic beads (HOOC-MBs) as pre-concentrator support and the amperometric transduction at screen-printed carbon electrodes (SPCEs). The immunoplatform involves a sandwich-type immunoassay assembled on HOOC-MBs through the specific capture/labeling of TIM-1 using capture antibodies and horseradish peroxidase (HRP)-conjugated biotinylated detection antibodies as biorecognition elements. The magnetic immunoconjugates were confined onto the working electrode (WE) surface of the SPCEs for amperometric detection using the hydroquinone/hydrogen peroxide/HRP (HQ/H2O2/HRP) redox system. The method allows the selective detection of TIM-1 protein over the 87-7500 pg mL-1 concentration range in only 45 min, with a limit of detection of 26 pg mL-1. The developed bioplatform was successfully applied to the analysis of breast and lung cancer cell extracts, providing the first quantitative results of the target glycoprotein in these types of samples.The financial support of PID2019-103899RB-I00 (Spanish Ministerio de Ciencia e Innovación) Research Projects and PI20CIII/00019 Grant from the AES-ISCIII Program co-founded by FEDER funds and the TRANSNANOAVANSENS-CM Program from the Comunidad de Madrid (Grant S2018/NMT-4349) are gratefully acknowledged. A.M-C. was supported by a FPU predoctoral contract supported by the Spanish Ministerio de Educación, Cultura y Deporte. J.Q. was founded by Minciencias, Mineducacion, MINCIT, and ICETEX through the Program Ecosistema Cientifico Cod. FP44842-211–2018, project number 58536. J.O. thanks support from the University of Antioquia and the Max Planck Society through the cooperation agreement 566–1, 2014.S

Dose-dependent improvement of cardiac function in a swine model of acute myocardial infarction after intracoronary administration of allogeneic heart-derived cells

Allogeneic cardiac-derived progenitor cells (CPC) without immunosuppression could provide an effective ancillary therapy to improve cardiac function in reperfused myocardial infarction. We set out to perform a comprehensive preclinical feasibility and safety evaluation of porcine CPC (pCPC) in the infarcted porcine model, analyzing biodistribution and mid-term efficacy, as well as safety in healthy non-infarcted swine.This work was mainly supported by the European FP7-HEALTH-2009-1.4-3, Grant Agreement 242038. In addition, it was partially supported by FEDER funds and grants from the Ministerio de Economia industria y Competitividad ISCIII (PI16/01172) co-funded by ERDF/ESF, “Investing in your future” and Junta de Extremadura Consejeria de Economía e Infraestructuras (IB16201) to VC, and the Spanish Ministry of Science and Innovation (SAF2015-70882-R; AEI/FEDER, UE) and the Instituto de Salud Carlos III (RETICS-RD12/0019/0018) to AB.Peer reviewe

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain : Large-Scale Epidemiological Study

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31-56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery

Correction : Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10, 2885

The authors wish to make the following corrections to this paper [...]

Desarrollo y estudio del potencial inmunomodulador de tres novedosas estrategias para la aplicación de la terapia celular

La terapia celular ha emergido en los últimos años como una nueva herramienta terapéutica para el tratamiento de diversas patologías. Sin embargo, la vía y tipo de administración de estas terapias son factores enormemente condicionantes para la correcta implantación del producto terapéutico y, por tanto, para su eficacia. En este sentido, es necesario el desarrollo de métodos y vías de administración alternativos que aseguren viabilidad y la correcta implantación de las células madre para conseguir la optimización de estas terapias. Esta tesis doctoral plantea estrategias alternativas para favorecer la implantación y aumentar el efecto terapéutico de las células madre adultas. Cada una de estas estrategias constituye un bloque con entidad propia que se desarrolla a lo largo de los diferentes apartados de este trabajo. La primera estrategia se centra en el uso combinado de las células madre mesenquimales (Mesenchymal Stem Cells, MSCs) con materiales quirúrgicos para favorecer la implantación y la actividad biológica de las células. La segunda estrategia aborda una nueva vía de administración en el contexto de la terapia celular para el tratamiento de lesiones de origen cardiovascular. En concreto, las células madre adultas son administradas por vía intrapericárdica, evaluando su biodistribución y actividad inmunomoduladora en un modelo de animal grande. Por último, para la tercera estrategia se evalúa la actividad inmunomoduladora de exosomas derivados de MSCs, y se realiza una comparativa de diferentes metodologías de aislamiento de dichas vesículas para su extrapolación y aplicación en el entorno clínico.In the recent years, stem cell therapy has emerged as a novel therapeutic tool for the treatment of a wide range of diseases. The administration route has a significant impact on the success of these therapies as it determines the correct implantation of the therapeutic product as well as its effectiveness. In this sense, the evaluation of new approaches, alternative implantation routes and techniques is urgently needed. This PhD work analyses different strategies to improve the implantation and the therapeutic effect of adult stem cells. The results of these strategies are discussed along the different sections of this thesis. The first strategy was focused in the combination of mesenchymal stem cells (Mesenchymal Stem Cells (MSCs) and surgical materials to enhance the implantation and biological activity of MSCs. The second strategy addresses an innovative administration route in the context of cardiovascular cell therapy. Concretely, adult stem cells were intrapericardially administered, evaluating their bio-distribution and immunomodulatory activity in a large animal model. Finally, the immunomodulatory activity of MSCs-derived exosomes was evaluated and different isolation methods were assessed for their extrapolation and application in the clinical context.Este trabajo ha sido financiado en parte por la Junta de Extremadura, el Fondo Social Europeo y los Fondos FEDER a través de las ayudas concedidas a Rebeca Blázquez (TE12066) y Javier García (TA13042 e IBI3123), así como por la ayuda a grupos catalogados de la Junta de Extremadura (GR15175), las ayudas de Redes temáticas de investigación cooperativa en salud (DR12/0042/0025 a Francisco Miguel Sánchez Margallo y Claudia Báez), el Séptimo Programa Marco Europeo (FP7-HEALTH-2009-1.4-3 242038) y por el centro de Cirugía de Mínima Invasión

Desarrollo y estudio del potencial inmunomodulador de tres novedosas estrategias para la aplicación de la terapia celular

La terapia celular ha emergido en los últimos años como una nueva herramienta terapéutica para el tratamiento de diversas patologías. Sin embargo, la vía y tipo de administración de estas terapias son factores enormemente condicionantes para la correcta implantación del producto terapéutico y, por tanto, para su eficacia. En este sentido, es necesario el desarrollo de métodos y vías de administración alternativos que aseguren viabilidad y la correcta implantación de las células madre para conseguir la optimización de estas terapias. Esta tesis doctoral plantea estrategias alternativas para favorecer la implantación y aumentar el efecto terapéutico de las células madre adultas. Cada una de estas estrategias constituye un bloque con entidad propia que se desarrolla a lo largo de los diferentes apartados de este trabajo. La primera estrategia se centra en el uso combinado de las células madre mesenquimales (Mesenchymal Stem Cells, MSCs) con materiales quirúrgicos para favorecer la implantación y la actividad biológica de las células. La segunda estrategia aborda una nueva vía de administración en el contexto de la terapia celular para el tratamiento de lesiones de origen cardiovascular. En concreto, las células madre adultas son administradas por vía intrapericárdica, evaluando su biodistribución y actividad inmunomoduladora en un modelo de animal grande. Por último, para la tercera estrategia se evalúa la actividad inmunomoduladora de exosomas derivados de MSCs, y se realiza una comparativa de diferentes metodologías de aislamiento de dichas vesículas para su extrapolación y aplicación en el entorno clínico.In the recent years, stem cell therapy has emerged as a novel therapeutic tool for the treatment of a wide range of diseases. The administration route has a significant impact on the success of these therapies as it determines the correct implantation of the therapeutic product as well as its effectiveness. In this sense, the evaluation of new approaches, alternative implantation routes and techniques is urgently needed. This PhD work analyses different strategies to improve the implantation and the therapeutic effect of adult stem cells. The results of these strategies are discussed along the different sections of this thesis. The first strategy was focused in the combination of mesenchymal stem cells (Mesenchymal Stem Cells (MSCs) and surgical materials to enhance the implantation and biological activity of MSCs. The second strategy addresses an innovative administration route in the context of cardiovascular cell therapy. Concretely, adult stem cells were intrapericardially administered, evaluating their bio-distribution and immunomodulatory activity in a large animal model. Finally, the immunomodulatory activity of MSCs-derived exosomes was evaluated and different isolation methods were assessed for their extrapolation and application in the clinical context.Este trabajo ha sido financiado en parte por la Junta de Extremadura, el Fondo Social Europeo y los Fondos FEDER a través de las ayudas concedidas a Rebeca Blázquez (TE12066) y Javier García (TA13042 e IBI3123), así como por la ayuda a grupos catalogados de la Junta de Extremadura (GR15175), las ayudas de Redes temáticas de investigación cooperativa en salud (DR12/0042/0025 a Francisco Miguel Sánchez Margallo y Claudia Báez), el Séptimo Programa Marco Europeo (FP7-HEALTH-2009-1.4-3 242038) y por el centro de Cirugía de Mínima Invasión

The immunomodulatory activity of extracellular vesicles derived from endometrial mesenchymal stem cells on CD4+ T cells is partially mediated by TGFbeta

Endometrial mesenchymal stem cells (endMSCs) reside in the basal and functional layer of human endometrium and participate in tissue remodelling, which is required for maintaining the regenerative capacity of the endometrium. The endMSCs are multipotent stem cells and exhibit immunomodulatory effects. This paper aimed to evaluate the regulatory effects of extracellular vesicles derived from endMSCs (EV-endMSCs) in the setting of T cell activation. In vitro stimulations of lymphocytes were performed in the presence of EV-endMSCs. These in vitro-stimulated lymphocytes were functionally and phenotypically characterized to distinguish CD4+ and CD8+ T cell differentiation subsets. Moreover, the inhibition of TGFβ was performed with neutralizing antibodies. The phenotype and nanoparticle tracking analysis of the EV-endMSCs demonstrated that they are similar in terms of size distribution to other mesenchymal stem cells-derived exosomes. The in vitro assays showed an immunomodulatory potential of these vesicles to counteract the differentiation of CD4+ T cells. The quantification of active TGFβ in EV-endMSCs was found to be very high when compared with extracellular vesicles-free concentrated supernatants. Finally, the neutralization of TGFβ significantly attenuated the immunomodulatory activity of EV-endMSCs. In summary, this is the first report demonstrating that EV-endMSCs exhibit a potent inhibitory effect against CD4+ T cell activation, which is partially mediated by TGFβ signalling.ISCIII cofunded by ERDF/ESF, Grant/Award Number: CP17/00021 to JGC; Consejeria de Economia e Infraestructuras, Junta de Extremadura cofinanced by FEDER, Grant/Award Number: IB16168 to JGC; GobEx (Ayuda a grupos catalogados de la Junta de Extremadura), Grant/Award Number: GR15175; Juan de la Cierva Incorporacion from the Spanish Ministry of Economy, Industry and Competitiveness, Grant/Award Number: IJCI-2014-19428 to BMG; Spanish Ministry of Economy and Competitiveness (MINECO), Grant/Award Number: BIO2015-67580-P; Carlos III Institute of Health-Fondo de Investigacion Sanitaria, Grant/Award Number: PRB2, PT13/0001/0017-ISCIII-SGEFI/FEDER; PBR3, PT17/0019/0003 ISCIII-SGEFI/FEDER; ProteoRed; Fundacion La Marato TV3, Grant/Award Number: 20153731(122/C/2015); CIBERCV, Grant/Award Numbers: CB16/11/00494 and CB16/11/00277; Ministerio de Ciencia, Innovacion y Universidades; Pro-CNIC FoundationS